On Thursday, Eli Lilly responded to the Trump administration’s plan to lower U.S. drug costs with a stunningly tone-deaf statement: the company threatened to raise prices in Europe to “align” them with what patients pay in other developed countries. This isn’t leadership—it’s corporate hostage-taking. Instead of addressing the fundamental issue of drug affordability in the…
Direct-to-consumer (DTC) marketing in pharma already walks a tightrope. The FDA is watching. Patients are skeptical. Trust in both pharma and AI is fragile. And now, some marketers are tempted to plug generative AI directly into patient-facing communications — from chatbots to automated follow-ups. That’s a mistake—a big one. 1. AI Doesn’t Understand Context Like…
In 2025, under the stewardship of Health and Human Services Secretary Robert F. Kennedy Jr., scientific integrity and public health are facing an alarming reckoning. His actions represent more than political maneuvering—they’re reshaping public health infrastructure in ways that could cost lives. 1. Eroding Vaccine Infrastructure and Expertise Kennedy halted nearly $500 million in funding for 22…